Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Exelixis, Inc.

Gilead vs. Exelixis: SG&A Cost Management Showdown

__timestampExelixis, Inc.Gilead Sciences, Inc.
Wednesday, January 1, 2014508290002983000000
Thursday, January 1, 2015573050003426000000
Friday, January 1, 20161161450003398000000
Sunday, January 1, 20171593620003878000000
Monday, January 1, 20182063660004056000000
Tuesday, January 1, 20192282440004381000000
Wednesday, January 1, 20202933550005151000000
Friday, January 1, 20214017150005246000000
Saturday, January 1, 20224598560005673000000
Sunday, January 1, 20235427050006090000000
Monday, January 1, 20244921280006091000000
Loading chart...

Cracking the code

Optimizing SG&A Costs: A Tale of Two Biotech Giants

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Gilead Sciences, Inc. and Exelixis, Inc. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Gilead's SG&A expenses have consistently been higher, peaking at approximately $6.1 billion in 2023. In contrast, Exelixis has shown a more conservative trajectory, with expenses rising from $51 million in 2014 to $543 million in 2023.

Despite Gilead's larger scale, Exelixis has managed to keep its SG&A expenses at about 9% of Gilead's, showcasing a leaner operational model. This comparison highlights the strategic differences in cost management between a biotech behemoth and a nimble competitor, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025